Study | Exclusion reasons | Remarks | Reference(s) | ||
---|---|---|---|---|---|
Candidate COVID-19 Vaccine (COV001), 2020 | randomized controlled trial |
Folegatti PM Lancet 2020 Aug 15;396(10249):467-478. 10.1016/S0140-6736(20)31604-4 |
|||
Babamahmoodi, 2021 | observational study | no control group |
Babamahmoodi F et al. researchsquare 10.21203/rs.3.rs-709499/v1 |
||
Tobaiqy M, 2021 | case series | no control group | retrospective descriptive study using spontaneous reports submitted to the EV database in the period from 17 February to 12 March 2021 |
Tobaiqy M Vaccines (Basel) 2021 Apr 16;9(4):393. 10.3390/vaccines9040393 |
|
NCT04276896, 0 | single-arm | no control group | |||
Barrett, 2020 | - | no control group | phase 1/2 | ||
Nanthapisal, 2022 | randomized controlled trial | no clinically relevant endpoint | To evaluate immunogenicity and reactogenicity of standard- versus low-doseChAdOx1 nCoV-19 vaccine booster after CoronaVac in healthy adults |
Nanthapisal S et al. medrxiv;2022.02.15.22270974v1 10.1101/2022.02.15.22270974 |